Alliance Pharma plc 44.1% potential upside indicated by RBC Capital Markets

Alliance Pharma plc with ticker (LON:APH) now has a potential upside of 44.1% according to RBC Capital Markets.



RBC Capital Markets set a target price of 60 GBX for the company, which when compared to the Alliance Pharma plc share price of 42 GBX at opening today (16/02/2024) indicates a potential upside of 44.1%. Trading has ranged between 34 (52 week low) and 73 (52 week high) with an average of 907,284 shares exchanging hands daily. The market capitalisation at the time of writing is £218,587,759.

Alliance Pharma plc is a United Kingdom-based consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The Company’s segments are strategic business units that represent different parts of the overall product portfolio, these being Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Changmin, Fazol Cream, Hydromol Ointment, Kelo-Stretch Cream, and others. It holds the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are sold around the world in more than 100 countries.